Introduction: A promising strategy that can lead to longer brain cell survival after an acute stroke is therapeutic hypothermia. It represents a controlled decrease in body temperature for therapeutic reasons. It is increasingly represented as a therapeutic option and is one of the most challenging treatments that improves neurological recovery and treatment outcome in patients with acute stroke. Aim: To examine the effect of therapeutic hypothermia on liver enzymes in patients with diagnosis of stroke. Methods: A total of 101 patients diagnosed with acute stroke were treated. The first group (n=40) were treated with conventional treatment and therapeutic hypothermia, while the second group (n=61) only with conventional treatment. Cooling of the body to a target body temperature of 34°C to 35°C was performed for up to 24 hours. Outcome (survival or death) of treatment was monitored, degree of disability was determined by National Institutes of Health Stroke Scale (NIHSS) and assessment of consciousness using the Glasgow Coma Scale (GCS). Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) values â€‹â€‹were taken at admission, after 24 hours, and were monitored upon discharge. Results: There was a significant difference in AST values at admission relative to disease outcome (p = 0.002), as well as for ALT (p = 0.008). In patients treated with therapeutic hypothermia, mean AST values decreased after 24 hours (32.50 to 31.00 IU/mL) as well as ALT values (27.50 to 26.50 IU/mL), without statistical significance. In the group of subjects who survived with sequela, AST values correlated with GCS (rho = -0.489; p = 0.002) and NIHSS (rho = 0.492; p = 0.003), ALT values correlated with GCS (rho = -0.356; p = 0.03) but not with NIHSS. Conclusion: AST and ALT values at admission correlate with the severity of the clinical picture. Therapeutic hypothermia is hepatoprotective and lowers AST and ALT values.
brain, metabolism, therapy.
Promoter CAG is more efficient than hepatocyteâ€‘targeting TBG for transgene expression via rAAV8 in liver tissues.
Kang J, Hang L, Zheng W, Luo J, Zhang X, Song Y, Liu A
Molecular medicine reports. 2022; 25(1):
Biovalue in Human Brain Banking: Applications and Challenges for Research in Neurodegenerative Diseases.
Methods in molecular biology (Clifton, N.J.). 2022; 2389(): 209-220
Editorial: Novel therapeutic approaches in chronic kidney disease and kidney transplantation: the draw of evolving integrated multimodal approaches in the targeted therapy era.
Tantisattamo E, Hanna RM, Kalantar-Zadeh K
Current opinion in nephrology and hypertension. 2022; 31(1): 1-5
Advancing Our Understanding of Brain Disorders: Research Using Postmortem Brain Tissue.
Curtis MA, Vedam-Mai V
Methods in molecular biology (Clifton, N.J.). 2022; 2389(): 201-208
Emerging roles of NRBF2/PI3KC3 axis in maintaining homeostasis of brain and guts.
Wu MY, Cai CZ, Yang C, Yue Z, Chen Y, Bian ZX, Li M, Lu JH
Neural regeneration research. 2022; 17(2): 323-324